Los Angeles Capital Management LLC Immuno Gen, Inc. Transaction History

Los Angeles Capital Management LLC

$24.7 Billion
Q3 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 06, 2024	SELL	$12.46 - $29.95 $59,994 - $144,209	-4,815 Reduced 10.25%	42,170 $1.25 Million
Q3 2023 Nov 06, 2023	BUY	$14.09 - $19.87 $24,023 - $33,878	1,705 Added 3.77%	46,985 $745,000
Q2 2023 Aug 03, 2023	BUY	$3.75 - $20.05 $169,800 - $907,864	45,280 New	45,280 $854,000
Q4 2021 Feb 03, 2022	SELL	$4.75 - $7.5 $413,525 - $652,935	-87,058 Closed	0 $0
Q2 2021 Aug 05, 2021	SELL	$5.79 - $8.6 $65,369 - $97,094	-11,290 Reduced 11.48%	87,058 $574,000
Q1 2021 May 05, 2021	SELL	$6.5 - $10.53 $399,295 - $646,857	-61,430 Reduced 38.45%	98,348 $796,000
Q4 2020 Feb 04, 2021	BUY	$3.7 - $7.66 $150,886 - $312,374	40,780 Added 34.27%	159,778 $1.03 Million
Q3 2020 Nov 02, 2020	SELL	$3.45 - $4.89 $346,656 - $491,347	-100,480 Reduced 45.78%	118,998 $428,000
Q2 2020 Aug 05, 2020	BUY	$3.32 - $5.34 $16,331 - $26,267	4,919 Added 2.29%	219,478 $1.01 Million
Q1 2020 May 04, 2020	BUY	$2.12 - $6.8 $143,318 - $459,700	67,603 Added 46.0%	214,559 $732,000
Q4 2019 Feb 07, 2020	BUY	$2.25 - $5.8 $330,651 - $852,344	146,956 New	146,956 $750,000
Q3 2019 Nov 07, 2019	SELL	$2.22 - $3.39 $126,096 - $192,552	-56,800 Closed	0 $0
Q2 2019 Jul 29, 2019	SELL	$1.8 - $3.3 $23,022 - $42,207	-12,790 Reduced 18.38%	56,800 $123,000
Q1 2019 Apr 25, 2019	SELL	$2.41 - $5.91 $20,051 - $49,171	-8,320 Reduced 10.68%	69,590 $189,000
Q4 2018 Feb 11, 2019	SELL	$3.94 - $9.7 $3,053 - $7,517	-775 Reduced 0.98%	77,910 $374,000
Q3 2018 Nov 05, 2018	SELL	$8.6 - $11.26 $29,842 - $39,072	-3,470 Reduced 4.22%	78,685 $745,000
Q2 2018 Jul 31, 2018	BUY	$9.52 - $12.15 $616,324 - $786,591	64,740 Added 371.75%	82,155 $799,000
Q1 2018 Apr 27, 2018	BUY	$6.7 - $12.95 $116,680 - $225,524	17,415 New	17,415 $183,000

Others Institutions Holding IMGN

# of Institutions

Shares Held

1.41M

Call Options Held

Put Options Held

View Full List

About ImmunoGen, Inc.

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

More about IMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Los Angeles Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Los Angeles Capital Management LLC with notifications on news.

Account